newsfilter
← Latest News
PR Newswire·

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration (FDA) notified the company that it